Armata Pharmaceuticals (ARMP) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Armata Pharmaceuticals (ARMP) is Neutral.

The composite score behind that read is -0.13, weighing +0.28 of bullish evidence against -0.33 bearish.

Armata Pharmaceuticals last closed at $3.63, -5.96% on the session.

Against the IVW growth benchmark the position is -6.76% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for ARMP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Armata Pharmaceuticals in the 95th percentile on return on equity, where 100 is best.

Armata Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $143.52M.

StockMap tracks Armata Pharmaceuticals as the 266th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Armata Pharmaceuticals ranks 240th of 381 in the group, against a group median of -0.08.